A First-Time-In-Human Phase i Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Solomon, Benjamin J ^a   Desai, Jayesh ^b   Rosenthal, Mark ^b   McArthur, Grant A ^a   Pattison, Scott T ^c   Pattison, Stacey L ^c   MacDiarmid, Jennifer ^c   Brahmbhatt, Himanshu ^c   Scott, Andrew M ^d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Engeneic Ltd   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CYTOKINE; LIPOPOLYSACCHARIDE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL MINICELL; CHILL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; REACTIVE ARTHRITIS; REPEATED DRUG DOSE; RIGOR; SOLID TUMOR; CLINICAL TRIAL; CYTOLOGY; DEMOGRAPHY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM;

ADULT; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CYTOKINES; DEMOGRAPHY; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PACLITAXEL; SALMONELLA TYPHIMURIUM;

EID: 84957109484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144559     Document Type: Article

References (19)

1. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer cell. 2007; 11 (5):431-45. Epub 2007/05/08. doi: 10.1016/j.ccr.2007.03.012 PMID: 17482133.
2. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nature biotechnology. 2009; 27(7):643-51. Epub 2009/06/30. doi: 10.1038/nbt.1547 PMID: 19561595.
3. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research. 1986; 46(12 Pt 1):6387-92. Epub 1986/12/01. PMID: 2946403.
4. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science (New York, NY). 2004; 303(5665):1818-22. Epub 2004/03/20. doi: 10.1126/science.1095833 PMID: 15031496.
5. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert opinion on therapeutic targets. 2004; 8(4):335-53. Epub 2004/07/23. doi: 10.1517/14728222.8.4.335 PMID: 15268628.
6. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Experimental cell research. 2003; 284(1):99-110. Epub 2003/03/22. PMID: 12648469.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England journal of medicine. 2004; 351(4):337-45. Epub 2004/07/23. doi: 10.1056/NEJMoa033025 PMID: 15269313.
8. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. The Journal of biological chemistry. 1981; 256(20):10435-41. Epub 1981/10/25. PMID: 6116707.
9. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC clinical pharmacology. 2006; 6:2. Epub 2006/01/18. doi: 10.1186/1472-6904-6-2 PMID: 16412237; PubMed Central PMCID: PMCPmc1382254.
10. Fiske MJ, Fredenburg RA, VanDerMeid KR, McMichael JC, Arumugham R. Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations. Journal of chromatography B, Biomedical sciences and applications. 2001; 753(2):269-78. Epub 2001/05/04. PMID: 11334340.
11. MacDiarmid JA, Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Current opinion in biotechnology. 2011; 22(6):909-16. Epub 2011/05/10. doi: 10.1016/j.copbio. 2011.04.008 PMID: 21550793.
12. Akira S, Takeda K. Toll-like receptor signalling. Nature reviews Immunology. 2004; 4(7):499-511. Epub 2004/07/02. doi: 10.1038/nri1391 PMID: 15229469.
13. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. The Journal of experimental medicine. 1993; 178(6):2207-11. Epub 1993/12/01. PMID: 8245792; PubMed Central PMCID: PMCPmc2191270.
14. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. The Journal of experimental medicine. 1991; 174(5):1209-20. Epub 1991/11/01. PMID: 1940799; PubMed Central PMCID: PMCPmc2119001.
15. Monkemoller V, Schuttpelz M, McCourt P, Sorensen K, Smedsrod B, Huser T. Imaging fenestrations in liver sinusoidal endothelial cells by optical localization microscopy. Physical chemistry chemical physics: PCCP. 2014; 16(24):12576-81. Epub 2014/05/17. doi: 10.1039/c4cp01574f PMID: 24830784.
16. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. The American journal of pathology. 2000; 156(4):1363-80. Epub 2000/04/07. doi: 10.1016/s0002-9440(10)65006-7 PMID: 10751361; PubMed Central PMCID: PMCPmc1876882.
17. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(8):4607-12. Epub 1998/05/16. PMID: 9539785; PubMed Central PMCID: PMCPmc22537.
18. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
19. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8(4):955-6. Epub 2002/04/12. PMID: 11948099.